[Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
Servicio de Medicina Intensiva, Hospital 12 de Octubre, Madrid, España. Electronic address: elbarea@gmail.com.
Jesús Abelardo
JA
Barea Mendoza
Servicio de Medicina Interna, Hospital 12 de Octubre, Madrid, España.
Iñigo
I
Gredilla Zubiría
Servicio de Medicina Interna, Hospital 12 de Octubre, Madrid, España.
Jesús
J
González Olmedo
Servicio de Medicina Interna, Hospital 12 de Octubre, Madrid, España.
Salvador
S
Mateo Alvarez
D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015984:Causality; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D017674:Hypophosphatemia / Q000139:chemically induced*; D007262:Infusions, Intravenous; D008297:Male; D008320:Maltose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D005290:Ferric Compounds; D005346:Fibroblast Growth Factors; C522335:ferric carboxymaltose; D008320:Maltose; D000089703:Fibroblast Growth Factor-23